191 related articles for article (PubMed ID: 32660904)
1. Complete Response of a Young Woman With MYD88
Pabon CM; Neff JL; Forns TE; Wang J
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
[No Abstract] [Full Text] [Related]
2. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
3. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
5. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
6. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
[TBL] [Abstract][Full Text] [Related]
7. Waldenström macroglobulinemia.
Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
[TBL] [Abstract][Full Text] [Related]
8. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Castellani F; Visentin A; Campagnolo M; Salvalaggio A; Cacciavillani M; Candiotto C; Bertorelle R; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32284437
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
12. Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Jafri H; Khan I; Sidda A; Khan NAJ; Kheetan M; Griswold D; Pacioles T
J Investig Med High Impact Case Rep; 2021; 9():23247096211021228. PubMed ID: 34078157
[TBL] [Abstract][Full Text] [Related]
13. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Treon SP; Meid K; Gustine J; Yang G; Xu L; Liu X; Patterson CJ; Hunter ZR; Branagan AR; Laubach JP; Ghobrial IM; Palomba ML; Advani R; Castillo JJ
J Clin Oncol; 2021 Feb; 39(6):565-575. PubMed ID: 32931398
[TBL] [Abstract][Full Text] [Related]
15. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
Richardson K; Castillo JJ; Sarosiek SR; Branagan AR; Flynn CA; Meid K; Gustine JN; Liu X; Kofides A; Liu S; Wolf JL; Kacena KA; Patterson CJ; Guerrera ML; Tsakmaklis N; Treon SP; Hunter ZR
Blood Adv; 2024 May; 8(9):2133-2137. PubMed ID: 38237078
[No Abstract] [Full Text] [Related]
16. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
17. Bing-Neel Syndrome: Update on the Diagnosis and Treatment.
Nanah A; Al Hadidi S
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e213-e219. PubMed ID: 34674984
[TBL] [Abstract][Full Text] [Related]
18. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
19. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
20. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
